Comparative effectiveness of combined high‐dosed Trospium and Solifenacin for severe OAB symptoms in age‐related aspect

ABSTRACT Increase of effectiveness of treatment for severe overactive bladder (OAB) symptoms in patients 40–65 and 66–80 years of aged with combined antimuscarinic drugs. This placebo‐controlled longitudinal study was performed on the basis of Regional Diagnostic Centre (Vladivostok city, Russian Federation) from 1 June 2011 to 30 December 2012. Assignment of patients (n = 299, average age: 67·1; women: 174 or 58·2%, men: 125 or 41·8%) was random blind. All patients were distributed into two age groups 40–65 and 66–80 years, and then into groups in accordance with treatment algorithm. Group A1 – patients below 65 years old treated with Trospium 60 mg/day + Soilfenacin 20 mg/day, Group A2 (n = 51; also below 65 years old): Trospium 30 mg/day + Soilfenacin 10 mg/day, Group A3 (n = 45, below 65 years old): Placebo. Group B1(n = 52; over 65 years old): Trospium 60 mg/day + Soilfenacin 20 mg/day, Group B2 (n = 54; over 65 years old): Trospium 30 mg/day + Soilfenacin 10 mg/day, Group B3 (n = 49, over 65 years old): Placebo. Period of treatment in all groups was 2 months. All patients underwent urodynamic examination at the beginning and at the end of the study. International Consultation on Incontinence Questionnaire‐Short Form (ICIQ‐SF) questionnaires and bladder diaries were used for evaluating clinical effectiveness of treatment and patients' satisfaction. Frequency of episodes of inco...
Source: International Journal of Urological Nursing - Category: Urology & Nephrology Authors: Tags: Research Paper Source Type: research